Hormonal
Adult weight gain is associated with a statistically significant increased risk of postmenopausal breast, endometrial, and ovarian cancers, as well as colon and kidney cancers, with risk increasing by approximately 6-39% per 5 kg of weight gain.
Avoiding adult weight gain is a proven strategy to reduce the risk of several cancers, particularly in postmenopausal women and men. Focus on maintaining a stable weight from early adulthood onwards, as even modest gains (5 kg) are linked to higher risks for breast, endometrial, ovarian, colon, and kidney cancers. This is especially important for postmenopausal women not using hormone replacement therapy.
For each 5 kg increase in adult weight gain, the summary relative risk was 1.11 (95% CI = 1.08 to 1.13) for postmenopausal breast cancer among no- or low-hormone replacement therapy (HRT) users, 1.39 (95% CI = 1.29 to 1.49) and 1.09 (95% CI = 1.02 to 1.16) for postmenopausal endometrial cancer among HRT nonusers and users, respectively, 1.13 (95% CI = 1.03 to 1.23) for postmenopausal ovarian cancer among no or low HRT users, 1.09 (95% CI = 1.04 to 1.13) for colon cancer in men. The relative risk of kidney cancer comparing highest and lowest level of adult weight gain was 1.42 (95% CI = 1.11 to 1.81).
Why this rating
Based on a dose-response meta-analysis of 50 prospective observational studies.
Source
Adult Weight Gain and Adiposity-Related Cancers: A Dose-Response Meta-Analysis of Prospective Observational Studies
NaNa Keum et al. · JNCI Journal of the National Cancer Institute · 2015
DOI 10.1093/jnci/djv088
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →